Site icon pharmaceutical daily

Alterity Therapeutics Presents at the American Academy of Neurology Annual Meeting

BusinessWire

MELBOURNE, Australia & SAN FRANCISCO–(BUSINESS WIRE)–Alterity Therapeutics Limited, (ASX: ATH, NASDAQ: ATHE) (“Alterity” or
“the Company”) will present clinical data from its lead drug candidate
PBT434 at the American Academy of Neurology Annual Meeting in
Philadelphia, USA, from 5-9th May 2019.

Alterity will feature prominently at the Annual Meeting with a Platform
Presentation on Sunday 5th May featuring data from the
company’s Phase 1 clinical trial and a Poster Presentation featuring
pre-clinical data on Thursday 9th May.

The American Academy of Neurology Annual Meeting is one of the largest
gatherings of clinicians and researchers focusing on neurology in the
world. It has been running for more than 70 years.

The Platform Presentation is titled: A First in Human Study of
PBT434, a Novel Small Molecule Inhibitor of α-Synuclein Aggregation
and will present first data from the current clinical study program.
Details of this presentation, which is to be delivered by David Stamler,
MD, Chief Medical Officer & Senior VP Clinical Development, will be
disclosed to investors concurrently with the presentation.

The Phase 1 Clinical Trial for PBT434 commenced in 2018 in Australia,
recruiting healthy adult and older adult (≥ 65) volunteers with the
primary goals of assessing the safety and tolerability of PBT434 after
single and multiple oral dose administration. Secondary goals include
evaluating pharmacokinetic measures that will allow Alterity understand
how PBT434 is absorbed and metabolised by the body.

The Poster Presentation appearing on Thursday 9th May is
titled: PBT434 Prevents α-Synuclein Aggregation, Neuron Loss, Motor
Dysfunction and Reduces Glial Cell Inclusions in a Transgenic Mouse
Model of Multiple System Atrophy1.

This study evaluated the efficacy of PBT434 in a mouse model of multiple
system atrophy (MSA), which is a rare and rapidly progressive
neurological disorder that affects adults. MSA is characterized by motor
symptoms similar to those found in Parkinson’s disease, loss of ability
to coordinate voluntary movements, and impaired ability to regulate
involuntary body functions such as blood pressure, bowel and bladder
control and sexual function. Symptoms typically commence between the
ages of 50 and 60 years of age and it has no known cause. The Poster
will be lodged to coincide with the session later in the week.

PBT434 is the first of a new generation of small molecules designed to
block the accumulation and aggregation of α-synuclein. α-synuclein
is of great interest because aggregated forms of the protein are
considered a pathological hallmark of Parkinsonian conditions and are a
recognised therapeutic target by neuroscientists and clinicians.

Session details:

Oral Presentation Session:

Poster Presentation Sessions:

Geoffrey Kempler, CEO and Chairman said: “The AAN is the most
prestigious gathering of clinicians and researching working in neurology
and we are very pleased to have such strong participation which speaks
to the novelty and promise of our PBT434 drug candidate for the
treatment of neurological diseases.”

End Note

The Company changed its name on 8 April 2019 from Prana Biotechnology
Limited to Alterity Therapeutics Limited, (ASX: ATH, NASDAQ:ATHE).

Investor enquiries IR@altertitytherapeutics.com

About Alterity Therapeutics Limited

Alterity’s lead candidate, PBT434, is the first of a new generation of
small molecules designed to inhibit the aggregation of pathological
proteins implicated in neurodegeneration. PBT434 has been shown to
reduce abnormal accumulation of α-synuclein and tau proteins in animal
models of disease by restoring normal iron balance in the brain. In this
way, it has excellent potential to treat various forms of atypical
Parkinsonism such as Multiple System Atrophy (MSA) and Progressive
Supranuclear Palsy (PSP).

For further information please visit the Company’s web site at www.alteritytherapeutics.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the
meaning of section 27A of the Securities Act of 1933 and section 21E of
the Securities Exchange Act of 1934. The Company has tried to
identify such forward-looking statements by use of such words as
“expects,” “intends,” “hopes,” “anticipates,” “believes,” “could,”
“may,” “evidences” and “estimates,” and other similar expressions, but
these words are not the exclusive means of identifying such statements.

Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements are
described in the sections titled “Risk Factors” in the Company’s filings
with the SEC, including its most recent Annual Report on Form 20-F as
well as reports on Form 6-K, including, but not limited to the
following: statements relating to the Company’s drug development
program, including, but not limited to the initiation, progress and
outcomes of clinical trials of the Company’s drug development program,
including, but not limited to, PBT434, and any other statements that are
not historical facts. Such statements involve risks and
uncertainties, including, but not limited to, those risks and
uncertainties relating to the difficulties or delays in financing,
development, testing, regulatory approval, production and marketing of
the Company’s drug components, including, but not limited to, PBT434,
the ability of the Company to procure additional future sources of
financing, unexpected adverse side effects or inadequate therapeutic
efficacy of the Company’s drug compounds, including, but not limited to,
PBT434, that could slow or prevent products coming to market, the
uncertainty of patent protection for the Company’s intellectual property
or trade secrets, including, but not limited to, the intellectual
property relating to PBT434.

Any forward-looking statement made by us in this press release is
based only on information currently available to us and speaks only as
of the date on which it is made. We undertake no obligation to
publicly updated any forward-looking statement, whether written or oral,
that may be made from time to time, whether as a result of new
information, future developments or otherwise.

1 PBT434 Prevents α-synuclein Aggregation, Neuron Loss,
Motor Dysfunction and Reduces Glial Cell Inclusions in a Transgenic
Mouse Model of Multiple System Atrophy [David Finkelstein1, Nadia
Stefanova2, Paul Adlard1, Margaret Bradbury3, David Stamler3 1Florey
Institute of Neuroscience, 2Medical University of Innsbruck, 3Prana
Biotechnology]

2 PBT434 Prevents α-synuclein Aggregation, Neuron Loss,
Motor Dysfunction and Reduces Glial Cell Inclusions in a Transgenic
Mouse Model of Multiple System Atrophy [David Finkelstein1, Nadia
Stefanova2, Paul Adlard1, Margaret Bradbury3, David Stamler3 1Florey
Institute of Neuroscience, 2Medical University of Innsbruck, 3Prana
Biotechnology]

Contacts

Investor Relations
Rebecca Wilson
E: rwilson@buchanwe.com.au
Tp:
+61 3 9866 4722

Exit mobile version